Cormorant Asset Management, LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001583977

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2026 · 57 positions · Total reported value $1.40B · Top-10 concentration 56.4% · Updated 2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

Turnover: 81.4% · 9 new · 37 cut · 2 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -24.1% · vs SPY -26.2% · Prev Value $1.95B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -13.0% · vs SPY -15.1% · Latest Value $1.40B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Cormorant Asset Management, LP disclosed 57 equity positions with a combined reported value of $1.40B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 56.4% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were PBLS ($149.04M), PRAX ($145.62M), RAPP ($82.57M). By sector, the heaviest allocations are Health Care 92.7%, Industrials 1.3%. Versus the prior quarter, allocation shifted toward Other (+4.3pp) and away from Health Care (-0.7pp), Industrials (-3.8pp).

Versus the prior quarter, Cormorant Asset Management, LP opened 9 new positions, trimmed 37 and fully exited 2, a turnover rate of 81.4% of positions. The portfolio's overlap with the prior quarter was 81% of names.

The largest new positions opened in Q3 2026 were GRTX ($37.86M), ATOS ($30.66M), ARTV ($30.32M).

Of the 2 positions fully exited versus the prior quarter, the largest were CRNX ($4.68M), ALT ($3.80M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • GRTX ELECTRA THERAPEUTICS INC · $37.86M
  • ATOS ATOSSA THERAPEUTICS INC · $30.66M
  • ARTV ARTIVA BIOTHERAPEUTICS INC · $30.32M
  • IRD OPUS GENETICS INC · $26.62M
  • VNDA VANDA PHARMACEUTICALS INC · $19.20M
  • CUE CUE BIOPHARMA INC · $16.18M
  • ACRS ACLARIS THERAPEUTICS INC · $9.21M
  • INBX INHIBRX BIOSCIENCES INC · $5.00M

Fully Exited (vs previous quarter)

  • CRNX CRINETICS PHARMACEUTICALS IN · prev qtr: $4.68M
  • ALT ALTIMMUNE INC · prev qtr: $3.80M

Insider Transactions (Form 4)

Latest Cormorant Asset Management, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-10-29 Sell Corbus Pharmaceuticals Holdings, Inc. 425,000 $4.10 SEC filing
2026-08-10 Buy BlossomHill Therapeutics, Inc. 312,500 $16.00 SEC filing
2026-08-10 Conversion BlossomHill Therapeutics, Inc. 1,701,541 — SEC filing
2026-08-10 Conversion BlossomHill Therapeutics, Inc. 1,599,993 — SEC filing
2026-04-28 Sell BRIGHT MINDS BIOSCIENCES INC. 109,331 $89.50 SEC filing

All insider transactions →

Fund Profile

Cormorant Asset Management, LP, based in Boston, MA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 57 positions worth $1.40B in total. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: BOSTON, MA, United States
  • SEC registration: 801-79513 (status: Approved), registered 2014-04-15
  • Regulatory AUM (Form ADV): $3.84B as of 2026-05-27
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 7 private funds, of which 1 hedge funds

Portfolio Structure

  • 57 positions · $1.40B reported value (Q3 2026)
  • Top 10 holdings = 56.4% of reported value
  • Largest position: PBLS (PARABILIS MEDICINES INC) at 10.7%
  • Average position size: $24.53M

Sector Tilt

  • Health Care 92.7%
  • Industrials 1.3%
  • Financials 1.1%
  • (classified holdings cover 95% of value)

Quarterly Activity

  • Q3 2026: 9 new, 1 added, 37 reduced, 2 exited
  • 10 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund is reducing exposure across most top-10 holdings (8/10), with only 2 held steady, suggesting a cautious stance on biotech/healthcare names despite sector concentration. Weight increases for PBLS and ANL are purely price-driven, not new buys. 2. Key moves: - Reduced: PRAX (-21.9% shares), EWTX (-25.9%), DNTH (-33.3%), ABVX (-37.0%), DRUG (-11.1%), ERAS (-16.7%), RAPP (-7.5%). - Added: None in top-10 (only 9 new positions total, not disclosed). - Held: PBLS, BBOT, ANL (no share changes). 3. Portfolio structure: Highly active, concentrated in Health Care (100% top-10), with high risk appetite (small-cap biotech/therapeutics). No passive ETFs apparent. 4. Per-holding one-liner: - PBLS: Parabilis Medicines (biopharma, unverified). - PRAX: Praxis Precision Medicines (cancer therapeutics). - RAPP: Rapport Therapeutics (neuroscience, unverified). - EWTX: Edgewise Therapeutics (rare diseases, unverified). - BBOT: BridgeBio Oncology (cancer, unverified). - ERAS: Erasca (oncology, unverified). - ANL: Adlai Nortye Group (biopharma, unverified). - DNTH: Dianthus Therapeutics (kidney disease, unverified). - ABVX: Abivax (immunology, unverified). - DRUG: Bright Minds Biosciences (CNS disorders, unverified). 5. Style summary: Trimming biotech positions amid caution, retaining select names with price-driven weight hikes.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 10:34

Sector Allocation

Health Care 92.7%
Financials 1.1%
Other 4.9%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 4.62M $149.04M 10.66%
10.66%
Hold
2 500.00K $145.62M 10.42%
10.42%
Reduce
3 2.46M $82.57M 5.91%
5.91%
Reduce
4 1.86M $75.52M 5.40%
5.40%
Reduce
5 17.88M $73.30M 5.24%
5.24%
Hold
6 5.00M $73.30M 5.24%
5.24%
Reduce
7 3.98M $63.65M 4.55%
4.55%
Hold
8 500.00K $44.02M 3.15%
3.15%
Reduce
9 425.00K $42.08M 3.01%
3.01%
Reduce
10 800.00K $39.86M 2.85%
2.85%
Reduce
11 3.37M $37.86M 2.71%
2.71%
New
12 2.86M $33.41M 2.39%
2.39%
Reduce
13 400.00K $33.32M 2.38%
2.38%
Reduce
14 1.79M $30.66M 2.19%
2.19%
New
15 1.03M $30.58M 2.19%
2.19%
Hold
16 1.82M $30.32M 2.17%
2.17%
New
17 2.47M $27.37M 1.96%
1.96%
Hold
18 5.50M $26.62M 1.90%
1.90%
New
19 2.11M $24.16M 1.73%
1.73%
Hold
20 375.00K $21.98M 1.57%
1.57%
Reduce
21 1.51M $20.16M 1.44%
1.44%
Reduce
22 962.90K $19.20M 1.37%
1.37%
New
23 5.75M $18.80M 1.34%
1.34%
Reduce
24 700.00K $17.46M 1.25%
1.25%
Reduce
25 800.00K $17.02M 1.22%
1.22%
Reduce
26 250.00K $16.45M 1.18%
1.18%
Reduce
27 625.28K $16.18M 1.16%
1.16%
New
28 2.34M $15.99M 1.14%
Form 4 · 1 →
1.14%
Hold
29 2.24M $15.89M 1.14%
1.14%
Reduce
30 2.08M $15.33M 1.10%
1.10%
Reduce
31 1.75M $15.12M 1.08%
1.08%
Reduce
32 450.00K $14.27M 1.02%
1.02%
Reduce
33 1.30M $13.78M 0.99%
0.99%
Hold
34 125.00K $11.13M 0.80%
0.80%
Reduce
35 275.00K $10.47M 0.75%
0.75%
Reduce
36 1.75M $9.21M 0.66%
0.66%
New
37 300.00K $8.73M 0.62%
0.62%
Add
38 4.50M $8.64M 0.62%
0.62%
Reduce
39 50.00K $5.00M 0.36%
0.36%
New
40 400.00K $4.57M 0.33%
0.33%
Reduce
41 300.00K $4.21M 0.30%
0.30%
New
42 3.57M $4.21M 0.30%
0.30%
Hold
43 50.00K $3.93M 0.28%
0.28%
Reduce
44 100.00K $3.66M 0.26%
0.26%
Reduce
45 75.00K $3.44M 0.25%
0.25%
Reduce
46 15.00K $3.42M 0.24%
0.24%
Reduce
47 125.00K $2.78M 0.20%
0.20%
Reduce
48 100.00K $2.43M 0.17%
0.17%
Reduce
49 940.00K $2.36M 0.17%
0.17%
Reduce
50 20.00K $2.28M 0.16%
0.16%
Reduce

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 80% R 80% F1 80% (modelled on 2026-Q2; 8/10 hit)

Low-confidence forecast This fund replaces about 33% of its Top-10 each quarter and backtests at F1 66% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (11 quarters)

Avg precision 66% · recall 66% · F1 66% · avg rank error 3.0 · Top-10 turnover 33%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 50% 50% 50% MLTX · AMAM · EYPT · BBIO · ACLX · RYZB · ALXO · ALPN · BMEA · PHVS MLTX · EYPT · ACLX · ALPN · BBIO · PRAX · CRBP · TARS · LBPH · EWTX
2024-Q2 60% 60% 60% MLTX · EYPT · ACLX · ALPN · BBIO · PRAX · CRBP · TARS · LBPH · EWTX MLTX · CRBP · ACLX · PCVX · LBPH · EYPT · RAPP · CRNX · EWTX · MRUS
2024-Q3 90% 90% 90% MLTX · CRBP · PCVX · ACLX · LBPH · EYPT · RAPP · CRNX · EWTX · MRUS MLTX · PCVX · ACLX · LBPH · EWTX · EYPT · RAPP · CRNX · PRAX · CRBP
2024-Q4 60% 60% 60% MLTX · PCVX · ACLX · EWTX · LBPH · EYPT · RAPP · CRNX · RNAM · CRBP MLTX · PRAX · JANX · ACLX · EWTX · NAMS · EYPT · RAPP · CRNX · INSM
2025-Q1 60% 60% 60% MLTX · PRAX · JANX · ACLX · EWTX · NAMS · EYPT · RAPP · CRNX · CNTA MLTX · EWTX · BBIO · ACLX · PRAX · EYPT · INSM · DRUG · HLXB · CNTA
2025-Q2 70% 70% 70% MLTX · EWTX · PRAX · BBIO · ACLX · EYPT · INSM · DRUG · HLXB · CNTA MLTX · EYPT · BBIO · PRAX · MRUS · EWTX · INSM · ACLX · NAMS · JANX
2025-Q3 60% 60% 60% MLTX · EYPT · BBIO · PRAX · MRUS · EWTX · INSM · ACLX · NAMS · JANX BBOT · ABVX · EYPT · RAPP · BBIO · EWTX · DRUG · ACLX · INSM · NAMS
2025-Q4 60% 60% 60% BBOT · ABVX · EYPT · RAPP · BBIO · NAMS · EWTX · DRUG · INSM · ACLX PRAX · BBOT · ABVX · QQQ · EYPT · IWM · XBI · RAPP · BBIO · DRUG
2026-Q1 50% 50% 50% PRAX · BBOT · ABVX · QQQ · EYPT · IWM · XBI · RAPP · BBIO · DRUG PRAX · BBOT · EYPT · EWTX · ERAS · RAPP · ALMS · ABVX · MLTX · DNTH
2026-Q2 90% 90% 90% PRAX · BBOT · EYPT · EWTX · MLTX · ALMS · ERAS · RAPP · DNTH · ABVX PRAX · BBOT · PBLS · RAPP · ERAS · EWTX · EYPT · ALMS · ABVX · DNTH
2026-Q3 ★ 80% 80% 80% PRAX · BBOT · PBLS · ERAS · RAPP · EWTX · EYPT · ALMS · ABVX · DNTH PBLS · PRAX · RAPP · EWTX · BBOT · ERAS · ANL · DNTH · ABVX · DRUG

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

Barra Factor Attribution

The disclosed long US equity book from the 2026-Q3 13F is held at its report-date weights and decomposed over 2026-09-30 ~ 2026-11-16. The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional factor returns and an EWMA factor covariance for risk. The “portfolio” is the visible 13F book, not the fund's true NAV.

13F periodQ3 2026 Attribution quarterQ4 2026 (in progress) Window2026-09-30 → 2026-11-16 Trading days33 Holdings8 Model coverage100.0%

The quarter is not complete yet; the window ends at the latest available price date, 2026-11-16, and will update as prices arrive.

Portfolio return-17.59%Buy & hold
QQQ synthetic benchmark-17.01%Liquidity weighted
Excess return-0.58%vs benchmark
Barra annualised vol54.2%Model estimate
Realised vol50.5%Annualised in window
Weighted beta1.36Raw exposure
Factor / specific risk37% / 63%Share of variance
Top-10 concentration100.0%Of reported value
Portfolio value (start = 100)78.485.091.798.3105.010-0110-2311-16Cormorant Asset Management, LPQQQ syntheticLiquid universe EW
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.

1. Performance

Metric Value Note
Portfolio return (buy & hold)-17.59%Disclosed long book
QQQ synthetic benchmark-17.01%Liquidity-weighted constituents
Model universe, equal weight-1.70%Opportunity-cost reference
Excess return-0.58%Portfolio − benchmark
Arithmetic return sum-17.63%Difference vs compounded is the cross term
Weighted raw beta1.36Weighted holding betas
Realised volatility (annualised)50.54%Daily returns in window
Barra model volatility (annualised)54.16%Factor + specific
Factor share of variance36.7%Barra factors
Specific share of variance63.3%Stock residuals
Reported value$73.4M13F long US equity

2. Return attribution

The -17.63% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.

Factor group Factors Contribution Share of |return|
Size & Liquidity 6 -0.41% -2.4%
Momentum & Growth 3 -5.42% -30.7%
Volatility & Tail Risk 7 -6.00% -34.0%
Industry 12 +6.98% 39.6%
Specific 1 -12.79% -72.5%
Return attribution (style + industry, %)-16.9-8.5+0.0+8.5+16.9Short-term Reversal+0.66Turnover-1.02Amihud Illiquidity-1.04Growth-2.05Beta+2.25Non-linear Size+2.51Size+2.96Skewness-3.59Mid Cap-3.82Momentum-4.03Kurtosis+4.03Residual Volatility+6.70Health Care+6.98Historical Volatility-15.66
Factor Type Exposure Factor return Contribution Share of |return|
Health Care Industry +1.00 +6.98% +6.98% 39.6%
Residual Volatility Style +2.04 +3.29% +6.70% 38.0%
Kurtosis Style +0.54 +7.51% +4.03% 22.9%
Size Style -1.52 -1.95% +2.96% 16.8%
Non-linear Size Style +2.48 +1.01% +2.51% 14.2%
Beta Style +0.51 +4.44% +2.25% 12.8%
Short-term Reversal Style +0.75 +0.87% +0.66% 3.7%
Leverage (Downside Vol) Style -0.14 -1.71% +0.24% 1.4%
Turnover Style +0.21 -4.80% -1.02% -5.8%
Amihud Illiquidity Style +2.34 -0.45% -1.04% -5.9%
Growth Style -1.17 +1.75% -2.05% -11.6%
Skewness Style +0.82 -4.39% -3.59% -20.3%
Mid Cap Style +1.97 -1.94% -3.82% -21.7%
Momentum Style +1.01 -4.00% -4.03% -22.8%
Specific Specific — — -12.79% -72.5%
Historical Volatility Style +1.12 -14.00% -15.66% -88.8%

3. Risk attribution

Annualised volatility is 54.16%; factor risk explains 36.7% of variance and specific risk 63.3%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.

Risk attribution (share of variance, %)-68.4-34.2+0.0+34.2+68.4Short-term Reversal-0.85Kurtosis-0.34Skewness+0.51Momentum+1.51Amihud Illiquidity+1.64Growth+1.73Non-linear Size+2.24Beta+2.51Residual Volatility+2.76Size+3.40Mid Cap+4.90Historical Volatility+6.14Health Care+10.52Specific+63.33
Factor Type Exposure Share of variance Vol contribution Share of vol
Specific Specific — 63.3% +34.30% 34.3%
Health Care Industry +1.00 10.5% +5.70% 5.7%
Historical Volatility Style +1.12 6.1% +3.32% 3.3%
Mid Cap Style +1.97 4.9% +2.65% 2.6%
Size Style -1.52 3.4% +1.84% 1.8%
Residual Volatility Style +2.04 2.8% +1.50% 1.5%
Beta Style +0.51 2.5% +1.36% 1.4%
Non-linear Size Style +2.48 2.2% +1.21% 1.2%
Growth Style -1.17 1.7% +0.94% 0.9%
Amihud Illiquidity Style +2.34 1.6% +0.89% 0.9%
Momentum Style +1.01 1.5% +0.82% 0.8%
Skewness Style +0.82 0.5% +0.28% 0.3%
Kurtosis Style +0.54 -0.3% -0.18% -0.2%
Short-term Reversal Style +0.75 -0.8% -0.46% -0.5%

4. Style exposures

Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.

Style exposures (z-score)-1.9-0.70.51.72.9Max DrawdownKurtosisSkewnessLeverage (Downside Vol)GrowthTurnoverAmihud IlliquidityLiquidityHistorical VolatilityResidual VolatilityShort-term ReversalMomentumBetaMid CapNon-linear SizeSizePortfolioQQQ benchmark
Style factor Portfolio QQQ benchmark Difference
Size -1.52 +2.10 -3.62
Non-linear Size +2.48 +1.68 +0.81
Mid Cap +1.97 +0.13 +1.85
Beta +0.51 +1.29 -0.79
Momentum +1.01 +0.72 +0.29
Short-term Reversal +0.76 -0.64 +1.40
Residual Volatility +2.04 -0.40 +2.44
Historical Volatility +1.12 +0.86 +0.26
Liquidity +0.01 +0.11 -0.11
Amihud Illiquidity +2.34 +1.16 +1.18
Turnover +0.21 +0.21 +0.01
Growth -1.17 +0.58 -1.76
Leverage (Downside Vol) -0.14 +0.14 -0.29
Skewness +0.82 +0.24 +0.58
Kurtosis +0.54 +0.21 +0.32
Max Drawdown -0.01 -0.08 +0.08

5. Industry allocation & Brinson

Industry allocation (weight, %)-10.020.050.080.0110.0Information TechnologyCommunication ServicesUtilitiesConsumer StaplesConsumer DiscretionaryIndustrialsHealth CarePortfolioQQQ benchmark
Sector Portfolio Benchmark Portfolio ret Benchmark ret Allocation Selection Interaction Total
Information Technology 0.0% 73.6% +0.00% -22.33% +3.83% +16.44% -16.44% +16.44%
Communication Services 0.0% 2.6% +0.00% -17.64% +0.01% +0.46% -0.46% +0.46%
Utilities 0.0% 0.8% +0.00% +11.13% -0.22% -0.09% +0.09% -0.09%
Consumer Staples 0.0% 0.8% +0.00% +15.26% -0.27% -0.13% +0.13% -0.13%
Consumer Discretionary 0.0% 8.8% +0.00% +3.76% -1.84% -0.33% +0.33% -0.33%
Industrials 0.0% 11.1% +0.00% +4.36% -2.39% -0.48% +0.48% -0.48%
Health Care 100.0% 1.7% -15.20% +8.29% +24.98% -0.41% -23.08% -15.34%
Total +23.98% +15.44% -38.92% +0.50%

6. Holdings & contribution

Symbol Name Sector Weight Return Contribution QoQ
AGMB AGOMAB THERAPEUTICS NV Health Care 37.30% -46.22% -17.24% Hold
TNGX TANGO THERAPEUTICS INC Health Care 23.80% -3.13% -0.74% Reduce
BBIO BRIDGEBIO PHARMA INC Health Care 22.42% +17.57% +3.94% Reduce
ROIV ROIVANT SCIENCES LTD Health Care 4.98% +5.58% +0.28% Reduce
ODTX ODYSSEY THERAPEUTICS INC Health Care 3.79% -12.87% -0.49% Reduce
NAMS NEWAMSTERDAM PHARMA COMPANY Health Care 3.31% -19.98% -0.66% Reduce
INSM INSMED INC Health Care 3.11% +7.66% +0.24% Reduce
GPCR STRUCTURE THERAPEUTICS INC Health Care 1.28% -40.61% -0.52% Reduce
Contribution rank Symbol Sector Weight Return Contribution
1 BBIO Health Care 22.42% +17.57% +3.94%
2 ROIV Health Care 4.98% +5.58% +0.28%
3 INSM Health Care 3.11% +7.66% +0.24%
4 ODTX Health Care 3.79% -12.87% -0.49%
5 GPCR Health Care 1.28% -40.61% -0.52%
6 NAMS Health Care 3.31% -19.98% -0.66%
7 TNGX Health Care 23.80% -3.13% -0.74%
8 AGMB Health Care 37.30% -46.22% -17.24%

7. Conclusions

  1. Over the attribution window 2026-09-30 → 2026-11-16 (33 trading days), the reported portfolio returned -17.59%, versus -17.01% for the QQQ synthetic benchmark — an excess of -0.58%.
  2. Return attribution: the largest positive style/industry contributions came from Health Care +6.98%, Residual Volatility +6.70%, Kurtosis +4.03%; the largest drags came from Historical Volatility -15.66%, Momentum -4.03%, Mid Cap -3.82%. Specific (stock-level) return contributed -12.79%.
  3. Risk attribution: Barra model volatility is 54.16% annualised; factor risk explains 37% of variance and specific risk 63%. The largest factor risk sources are Health Care 10.5%, Historical Volatility 6.1%, Mid Cap 4.9%.
  4. Style tilt: size -1.52, momentum +1.01, volatility +1.12, liquidity +0.01; the weighted raw beta is 1.36. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
  5. Industry: the largest overweight versus the benchmark is Health Care (+98.3 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +23.98%, selection +15.44% and interaction -38.92%.
  6. Concentration: the top-10 positions are 100.0% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
  • 13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
  • Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
  • Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
  • The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
  • Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
  • 13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
  • Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.

FAQ

What did Cormorant Asset Management, LP buy in 2026-Q3?

In its 2026-Q3 13F filing, Cormorant Asset Management, LP reported 57 equity positions worth $1.40B in aggregate; its largest disclosed positions were PBLS ($149.04M), PRAX ($145.62M), RAPP ($82.57M).

How large is Cormorant Asset Management, LP's portfolio?

Cormorant Asset Management, LP reported $1.40B of long equity holdings across 57 positions as of 2026-Q3. Top-10 holdings account for 56.4% of reported value.

What is Cormorant Asset Management, LP's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/cormorant-asset-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →